StreetAlpha.app
Home › Stocks › ALVO

Alvotech (ALVO)

Healthcare
$4.37
▼ −0.79%
LAST CLOSE · NOV 17

Alvotech develops and manufactures biosimilar medicines, sold through pharmaceutical partners to patients worldwide. It last closed at $4.37 on Nov 17, down 0.79% on the day. The average 12-month price target from 3 analysts is $8.00 (+83.1% from the last close), with a high of $9.00 and a low of $7.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ALVO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$586.3M
+19.7% vs a year ago
Net income
$27.9M
4.8% margin
Free cash flow
−$114.7M
−19.6% margin
Operating margin
13.3%
$78.2M operating income
Balance sheet
Cash & equivalents
$172.4M
At Dec 31
Debt
$1.3B
At Dec 31
Shareholder equity
−$284.5M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $36.8M$36.8MFY2021FY2022: $83.0M$83.0MFY2022FY2023: $91.4M$91.4MFY2023FY2024: $489.7M$489.7MFY2024FY2025: $586.3M$586.3MFY2025

From ALVO's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ALVO in the past 90 days
Average 12-month target
$8.00
▲ 83.1% upside

Based on 3 analysts who set a price target on ALVO in the past 90 days. The average target is $8.00, with a high of $9.00 and a low of $7.00, compared with the last close of $4.37.

Low $7.00Avg $8.00High $9.00
Blue marker: last close $4.37
Highest target$9.00
Average target$8.00
Lowest target$7.00
Latest rating changes
JefferiesInitiated
Nov 10Buy$9
BarclaysUpgrade
Sep 16Buy$8
B of A SecuritiesInitiated
Aug 24Buy$7
DateFirmActionRatingPrice target
Nov 10JefferiesInitiatedBuy$9
Sep 16BarclaysUpgradeBuy$8
Aug 24B of A SecuritiesInitiatedBuy$7
Loading…

Technical Analysis

ALVO · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 7% below its 20 day and 19% below its 50 day average. It is 4% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the Pivot at $4.36, and the nearest resistance the Pivot R1 at $4.49.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 7.1%/day
Key levels
$6.5352 week high+49.4%
$5.2050 day average+19.0%
$4.6820 day average+7.1%
$4.59Swing high (Jun 9)+5.0%
$4.58100 day average+4.8%
$4.49Pivot R1+2.7%
$4.37Last close
$4.36Pivot−0.2%
$4.23Pivot S1−3.2%
$4.17200 day average−4.6%
$3.75Swing low (Aug 20)−14.2%
$2.9452 week low−32.7%
Indicators
RSI (14)40.56Middle of its rangeNeutral
MACD-0.19Below its signal lineBearish
Stochastic20.9Middle of its rangeNeutral
ADX (14)17.0No clear trend
Williams %R-73.7Oversold below −80, overbought above −20Neutral
CCI (20)-132.4Oversold below −100, overbought above 100Oversold
Rate of change−3.7%Change over 10 sessionsBearish
ATR (14)$0.31Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ALVO

What happened before

See how ALVO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALVO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALVO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ALVO in the last 90 days.

Loading…

See today’s whale options flow across the market →

ALVO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲50 buying vs 23 selling
  • ▲Shares held by funds +21.8%
  • ▲Funds holding +7
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding7972+9.7%
In funds' top 10220.0%
Held by funds–––
New / increased17 / 3322 / 21+16.3%
Reduced / sold out14 / 919 / 7−11.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALVO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALVO is in one of them and how their past ALVO trades turned out.

ALVO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALVO in an article yet. Here's the latest on the wider market.

About Alvotech

Alvotech is a biotechnology company based in Luxembourg that develops and manufactures biosimilars, which are lower cost versions of established biologic medicines. Its approved products copy treatments for conditions such as arthritis, psoriasis, Crohn's disease, macular degeneration and osteoporosis. The company handles research, manufacturing and regulatory work in-house and licenses its products to pharmaceutical partners that sell them in global markets, serving patients worldwide.

Headquarters
Luxembourg, Luxembourg